1
|
Tondato F, Zeng H, Goodchild T, Ng FS, Chronos N, Peters NS. Autologous Dermal Fibroblast Injections Slow Atrioventricular Conduction and Ventricular Rate in Atrial Fibrillation in Swine. Circ Arrhythm Electrophysiol 2015; 8:439-46. [DOI: 10.1161/circep.114.001536] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2014] [Accepted: 01/20/2015] [Indexed: 11/16/2022]
Abstract
Background—
Nonpharmacological ventricular rate control in atrial fibrillation (AF) without producing atrioventricular (AV) block remains a clinical challenge. We investigated the hypothesis that autologous dermal fibroblast (ADF) injection into the AV nodal area would reduce ventricular response during AF without causing AV block.
Methods and Results—
Fourteen pigs underwent electrophysiology study before, immediately, and 28 days after ≈200 million cultured ADFs (n=8) or saline (n=6) were injected under electroanatomical guidance in the AV nodal area, with continuous 28-day ECG recording. In the ADF group at 28 days postinjection, there were prolongations of PR interval (after versus before: 130±13 versus 113±14 ms,
P
=0.04), of AH interval during both sinus rhythm (92±13 versus 76.8±8 ms,
P
<0.01) and atrial pacing at 400 ms (102±13 versus 91±9 ms,
P
<0.01), and of AV node Wenckebach cycle length (230±19 versus 213±24 ms,
P
<0.01), with no changes in the control group. The RR interval during induced AF 28 days after injections was 24% longer in ADF-treated group compared with controls (488±120 versus 386±116 ms,
P
<0.001). Histological analysis revealed presence of ADF-labeled cells in the AV nodal area at 28 days. Transient accelerated junctional rhythm during injections, and transient nocturnal Mobitz I AV conduction occurred early postinjection in both groups.
Conclusions—
Cells survived for 4 weeks and significantly slowed AV conduction and ventricular rate in acutely induced AF. Critically, despite a large number of injections in the AV nodal area and marked effects on AV conduction, AV block did not occur. Further studies are necessary to determine the clinical feasibility and safety of this strategy for ventricular rate control in AF.
Collapse
Affiliation(s)
- Fernando Tondato
- From the Myocardial Function Section, Imperial College & Imperial NHS Trust, London, United Kingdom (F.T., N.S.P.); and Saint Joseph’s Translational Research Institute/Saint Joseph’s Hospital of Atlanta, GA (F.T., H.Z., T.G., F.S.N., N.C.)
| | - Hong Zeng
- From the Myocardial Function Section, Imperial College & Imperial NHS Trust, London, United Kingdom (F.T., N.S.P.); and Saint Joseph’s Translational Research Institute/Saint Joseph’s Hospital of Atlanta, GA (F.T., H.Z., T.G., F.S.N., N.C.)
| | - Traci Goodchild
- From the Myocardial Function Section, Imperial College & Imperial NHS Trust, London, United Kingdom (F.T., N.S.P.); and Saint Joseph’s Translational Research Institute/Saint Joseph’s Hospital of Atlanta, GA (F.T., H.Z., T.G., F.S.N., N.C.)
| | - Fu Siong Ng
- From the Myocardial Function Section, Imperial College & Imperial NHS Trust, London, United Kingdom (F.T., N.S.P.); and Saint Joseph’s Translational Research Institute/Saint Joseph’s Hospital of Atlanta, GA (F.T., H.Z., T.G., F.S.N., N.C.)
| | - Nicolas Chronos
- From the Myocardial Function Section, Imperial College & Imperial NHS Trust, London, United Kingdom (F.T., N.S.P.); and Saint Joseph’s Translational Research Institute/Saint Joseph’s Hospital of Atlanta, GA (F.T., H.Z., T.G., F.S.N., N.C.)
| | - Nicholas S. Peters
- From the Myocardial Function Section, Imperial College & Imperial NHS Trust, London, United Kingdom (F.T., N.S.P.); and Saint Joseph’s Translational Research Institute/Saint Joseph’s Hospital of Atlanta, GA (F.T., H.Z., T.G., F.S.N., N.C.)
| |
Collapse
|
3
|
Manning C, Schwartz A, Liu W, Xie J, Havlioglu N, Sakiyama-Elbert S, Silva M, Xia Y, Gelberman R, Thomopoulos S. Controlled delivery of mesenchymal stem cells and growth factors using a nanofiber scaffold for tendon repair. Acta Biomater 2013; 9:6905-14. [PMID: 23416576 DOI: 10.1016/j.actbio.2013.02.008] [Citation(s) in RCA: 98] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2012] [Revised: 02/02/2013] [Accepted: 02/05/2013] [Indexed: 12/11/2022]
Abstract
Outcomes after tendon repair are often unsatisfactory, despite improvements in surgical techniques and rehabilitation methods. Recent studies aimed at enhancing repair have targeted the paucicellular nature of tendon for enhancing repair; however, most approaches for delivering growth factors and cells have not been designed for dense connective tissues such as tendon. Therefore, we developed a scaffold capable of delivering growth factors and cells in a surgically manageable form for tendon repair. Platelet-derived growth factor BB (PDGF-BB), along with adipose-derived mesenchymal stem cells (ASCs), were incorporated into a heparin/fibrin-based delivery system (HBDS). This hydrogel was then layered with an electrospun nanofiber poly(lactic-co-glycolic acid) (PLGA) backbone. The HBDS allowed for the concurrent delivery of PDGF-BB and ASCs in a controlled manner, while the PLGA backbone provided structural integrity for surgical handling and tendon implantation. In vitro studies verified that the cells remained viable, and that sustained growth factor release was achieved. In vivo studies in a large animal tendon model verified that the approach was clinically relevant, and that the cells remained viable in the tendon repair environment. Only a mild immunoresponse was seen at dissection, histologically, and at the mRNA level; fluorescently labeled ASCs and the scaffold were found at the repair site 9days post-operatively; and increased total DNA was observed in ASC-treated tendons. The novel layered scaffold has the potential for improving tendon healing due to its ability to deliver both cells and growth factors simultaneously in a surgically convenient manner.
Collapse
|
4
|
Bonetto F, Srinivas M, Heerschap A, Mailliard R, Ahrens ET, Figdor CG, de Vries IJM. A novel (19)F agent for detection and quantification of human dendritic cells using magnetic resonance imaging. Int J Cancer 2010; 129:365-73. [PMID: 20839261 DOI: 10.1002/ijc.25672] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2010] [Accepted: 08/17/2010] [Indexed: 01/18/2023]
Abstract
Monitoring of cell therapeutics in vivo is of major importance to estimate its efficacy. Here, we present a novel intracellular label for (19)F magnetic resonance imaging (MRI)-based cell tracking, which allows for noninvasive, longitudinal cell tracking without the use of radioisotopes. A key advantage of (19)F MRI is that it allows for absolute quantification of cell numbers directly from the MRI data. The (19)F label was tested in primary human monocyte-derived dendritic cells. These cells took up label effectively, resulting in a labeling of 1.7 ± 0.1 × 10(13) (19)F atoms per cell, with a viability of 80 ± 6%, without the need for electroporation or transfection agents. This results in a minimum detection sensitivity of about 2,000 cells/voxel at 7 T, comparable with gadolinium-labeled cells. Comparison of the detection sensitivity of cells labeled with (19)F, iron oxide and gadolinium over typical tissue background showed that unambiguous detection of the (19)F-labeled cells was simpler than with the contrast agents. The effect of the (19)F agent on cell function was minimal in the context of cell-based vaccines. From these data, we calculate that detection of 30,000 cells in vivo at 3 T with a reasonable signal to noise ratio for (19)F images would require less than 30 min with a conventional fast spin echo sequence, given a coil similar to the one used in this study. This is well within acceptable limits for clinical studies, and thus, we conclude that (19)F MRI for quantitative cell tracking in a clinical setting has great potential.
Collapse
Affiliation(s)
- Fernando Bonetto
- Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
| | | | | | | | | | | | | |
Collapse
|
5
|
Kiss I, Tibold A, Halmosi R, Bartha É, Koltai K, Orsós Z, Bujdosó L, Ember I. Enhancement of Organ Regeneration in Animal Models by a Stem Cell-Stimulating Plant Mixture. J Med Food 2010; 13:599-604. [DOI: 10.1089/jmf.2009.0013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Affiliation(s)
- István Kiss
- Institute of Preventive Medicine, Pécs University of Sciences, Pécs; Hungary
| | - Antal Tibold
- Institute of Preventive Medicine, Pécs University of Sciences, Pécs; Hungary
| | - Róbert Halmosi
- 1st Department of Internal Medicine, Faculty of Medicine, Pécs University of Sciences, Pécs; Hungary
| | - Éva Bartha
- 1st Department of Internal Medicine, Faculty of Medicine, Pécs University of Sciences, Pécs; Hungary
| | - Katalin Koltai
- 1st Department of Internal Medicine, Faculty of Medicine, Pécs University of Sciences, Pécs; Hungary
| | - Zsuzsanna Orsós
- Institute of Preventive Medicine, Pécs University of Sciences, Pécs; Hungary
| | - László Bujdosó
- Veszprém County Institute, Public Health and Health Officer's National Service, Veszprém, Hungary
| | - István Ember
- Institute of Preventive Medicine, Pécs University of Sciences, Pécs; Hungary
| |
Collapse
|
6
|
Mayorga M, Finan A, Penn M. Pre-transplantation specification of stem cells to cardiac lineage for regeneration of cardiac tissue. Stem Cell Rev Rep 2009; 5:51-60. [PMID: 19184567 DOI: 10.1007/s12015-009-9050-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2008] [Accepted: 01/08/2009] [Indexed: 02/07/2023]
Abstract
Myocardial infarction (MI) is a lead cause of mortality in the Western world. Treatment of acute MI is focused on restoration of antegrade flow which inhibits further tissue loss, but does not restore function to damaged tissue. Chronic therapy for injured myocardial tissue involves medical therapy that attempts to minimize pathologic remodeling of the heart. End stage therapy for chronic heart failure (CHF) involves inotropic therapy to increase surviving cardiac myocyte function or mechanical augmentation of cardiac performance. Not until the point of heart transplantation, a limited resource at best, does therapy focus on the fundamental problem of needing to replace injured tissue with new contractile tissue. In this setting, the potential for stem cell therapy has garnered significant interest for its potential to regenerate or create new contractile cardiac tissue. While to date adult stem cell therapy in clinical trials has suggested potential benefit, there is waning belief that the approaches used to date lead to regeneration of cardiac tissue. As the literature has better defined the pathways involved in cardiac differentiation, preclinical studies have suggested that stem cell pretreatment to direct stem cell differentiation prior to stem cell transplantation may be a more efficacious strategy for inducing cardiac regeneration. Here we review the available literature on pre-transplantation conditioning of stem cells in an attempt to better understand stem cell behavior and their readiness in cell-based therapy for myocardial regeneration.
Collapse
Affiliation(s)
- Maritza Mayorga
- Skirball Laboratory for Cardiovascular Cellular Therapeutics, Center for Cardiovascular Cell Therapy, Departments of Cardiovascular Medicine and Stem Cell Biology and Regenerative Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
| | | | | |
Collapse
|